Study Confirms Ability of the Prosigna Assay to Assess Risk of Late Distant Recurrence in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer

[Business Wire] – NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that a study published online in Clinical Cancer Research showed that the PAM50 assay, on whic more

View todays social media effects on NSTG

View the latest stocks trending across Twitter. Click to view dashboard

See who NanoString is hiring next, click here to view